Zobrazeno 1 - 10
of 337
pro vyhledávání: '"Daniel A. Pollyea"'
Autor:
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-tar
Externí odkaz:
https://doaj.org/article/1e698dc2b5034f73b534561525fe0273
Autor:
Amanda C. Winters, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Grace Bosma, Diana Abbott, Nicholas Miltgen, Ji Yuan, Amy L. Treece, Bradford J. Siegele, Mark D. Ewalt, Jonathan A. Gutman, Craig T. Jordan, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool fo
Externí odkaz:
https://doaj.org/article/dd1f3941b21d43f7a99618a3961ccd30
Autor:
Amanda C. Winters, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Externí odkaz:
https://doaj.org/article/c4874fcfc444493d8047ce88f5a8b478
Autor:
Keith Pratz, Courtney Dinardo, Martha L Arellano, Michael Thirman, Vinod Pullarkat, Pamela S. Becker, B. Douglas Smith, Meng Zhang, Michael E Werner, Jalaja Potluri, Daniel A. Pollyea
Publikováno v:
HemaSphere, Vol 7, p e68978fe (2023)
Externí odkaz:
https://doaj.org/article/9d932cfaecc64a378a4df2ef7714d55c
Autor:
Marina Konopleva, Courtney D. Dinardo, Yan Sun, Sanam Loghavi, Paul Jung, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea
Publikováno v:
HemaSphere, Vol 7, p e160928c (2023)
Externí odkaz:
https://doaj.org/article/feb327d309ba482292b12a9757915013
Autor:
Emily M. Kudalkar, Changlee Pang, Mary M. Haag, Daniel A. Pollyea, Manali Kamdar, Gang Xu, Meng Su, Billie Carstens, Karen Swisshelm, Liming Bao
Publikováno v:
Molecular Cytogenetics, Vol 15, Iss 1, Pp 1-9 (2022)
Abstract Background 21q22 amplification is a rare cytogenetic aberration in acute myeloid leukemia (AML). So far, the cytogenomic and molecular features and clinical correlation of 21q22 amplification in AML have not been well-characterized. Case pre
Externí odkaz:
https://doaj.org/article/d5c884544b7a49b19e6e0e52fa8bb4f5
Autor:
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigat
Externí odkaz:
https://doaj.org/article/4bed77ea2bb644d486a34c85f8f12b19
Autor:
Brett Stevens, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 108, Iss 7 (2023)
Externí odkaz:
https://doaj.org/article/b18e123bc433468784fdd76b4e520b63
Autor:
Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 58-68 (2020)
Abstract Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older patients. We analyzed diagnostic and mole
Externí odkaz:
https://doaj.org/article/b36efed85da84efcbaf5ae149d394d44
Autor:
Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized
Externí odkaz:
https://doaj.org/article/eb1cbed6f88d4b89add1a17240cfd403